RUNX1 and nonpapillary renal cell carcinoma: Two promising candidates for future validations based on their known connection to ccRCC are SLC16A3 (monocarboxylate transporter 4), which correlates with poorer relapse-free survival and functionally sustains the Warburg effect and survival in ccRCC cells [81], and RUNX1, which correlates with poorer clinical survival and functionally drives ccRCC [82].